ÌÇÐÄvlog´«Ã½

Therapeutic Drug Monitoring Market Analysis

The Therapeutic Drug Monitoring Market size is estimated at USD 1.25 billion in 2024, and is expected to reach USD 1.94 billion by 2029, growing at a CAGR of 9.12% during the forecast period (2024-2029).

Globally, the COVID-19 pandemic put enormous pressure on the healthcare system. Hospitals were understaffed and overworked. The urgent need for an accurate and rapid diagnosis of SARS-CoV-2 infection was critical as global healthcare systems continue to operate during the COVID-19 pandemic. In particular, serological and immunological testing of infected asymptomatic and symptomatic individuals was in high demand. Thus, COVID-19 impacted the market profoundly. As per the study published in Expert Review of Clinical Immunology in June 2021, enzyme-linked immunosorbent assays (ELISAs), chemiluminescent immunoassays (CLIAs), and lateral flow immunoassays (LFIAs) were the principal methodologies of serology-based tests for the detection of SARS-CoV-2.

Furthermore, according to the study titled "Rapid chromatographic immunoassay-based evaluation of COVID-19," published in February 2021, rapid chromatographic immunoassay-based test offered quick and accurate detection of COVID-19 and possessed excellent specificity and moderate sensitivity. Thus, the COVID-19 pandemic had a favorable impact on the market initially. As the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period of the study.

Increasing prevalence of cancers, neurological conditions, HIV, autoimmune and cardiac diseases, and growing R&D activities and clinical trials to expand the application of technologies in various indications. In August 2021, the Journal of Clinical Neurology cited epilepsy as the third most common neurological disorder after stroke and dementia, affecting approximately 70 million patients worldwide. According to WHO's 2021 data, more than 55 million people will live with dementia worldwide. Nearly 10 million new cases will be reported every year. Alzheimer's disease is the most common form of dementia and may contribute to 60-70% of the cases. Therefore, increasing chances of such diseases are anticipated to propel the market growth over the forecast period.

Moreover, various initiatives by the market players, such as product launches and mergers and acquisitions, are expected to propel the market's growth. For instance, in May 2022, THERADIAG, a company specializing in vitro diagnostics and theragnostic, reported the launch of ez-Track1, an accurate Point-of-Care Testing (POCT) solution for therapeutic drug monitoring. Such advancement in drug monitoring technology is expected to boost the market over the forecast period.

However, the reluctance of healthcare providers to implement therapeutic drug monitoring services in emerging nations is likely to hinder market growth over the forecast period.

Therapeutic Drug Monitoring Industry Segmentation

Therapeutic drug monitoring is the clinical practice of measuring the concentration of specific drugs with a narrow therapeutic index and/or their breakdown products (metabolites) at timed intervals in a patient's bloodstream. These systems help to maintain a relatively constant concentration of the drug in the blood required to show therapeutic effects and, thus, assist in assessing individual dosage regimens.

Therapeutic Drug Monitoring Market is Segmented by Technology (Immunoassays and Proteomic Technologies), Drug Class (Antiarrhythmic Drugs, Immunosuppressants, Antiepileptic Drugs, and Other Drug Classes), End-user (Hospitals, Diagnostic Centers, and Other End-users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers the value (in USD million) for the above segments.